News | January 10, 2022
Arch Pharmalabs signs agreement with Orchem Technologies to use SMB platform
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
Simulated Moving Bed (SMB) technology is a highly engineered process for implementing chromatographic separation
Agreement to utilize Exscientia’s AI-based capabilities and personalised medicine platform from target identification through patient selection. It will receive an upfront cash payment of US $ 100 million with the potential of US $ 5.2 billion in total milestones plus tiered royalties
Partnering to build biosynthesis processes and a pharmaceutical production platform
It is a novel oral NLRP3 inflammasome inhibitor
This further adds to Biocon’s portfolio of vertically integrated complex drug products
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
The NDA for Desidustat is based on positive data from the DREAM-ND and DREAM-D Phase 3 trials in patients with Chronic Kidney Disease (CKD) Not on Dialysis and Dialysis
The centre has an initial capacity of 500 FTEs
Key takeaways of recent quarter & conference call highlights
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
Subscribe To Our Newsletter & Stay Updated
